Takeda Pharmaceutical Co. shares on Tuesday fell their farthest in 20 years in Tokyo trading over concern one of its most promising experimental medicines will be delayed.
Japan’s largest drugmaker slumped as much as 12 percent, or ¥1,000, the maximum allowed by the Tokyo Stock Exchange, to ¥7,060 after analysts cut their ratings on the shares, citing the delay.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.